NCT07392060
Not yet recruiting
Phase 3
A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Shanghai Jiatan Pharmatech Co., Ltd0 sites440 target enrollmentStarted: February 28, 2026Last updated:
Overview
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Enrollment
- 440
- Primary Endpoint
- Overall survival in cervical cancer patients who have failed at least one prior line of platinum-based therapy
Overview
Brief Summary
This is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior platinum-based systemic therapy, as assessed by overall survival (OS).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The subject voluntarily participates in this clinical study, has provided signed informed consent prior to the initiation of any screening procedures, and is able to understand and comply with the study requirements.
- •Aged 18 to 75 years (inclusive, calculated on the day of signing the informed consent form).
- •Histologically or cytologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- •Not eligible for curative treatment with surgery, radiotherapy, or chemoradiotherapy.
- •Willing to undergo a biopsy during the screening period to provide fresh tumor tissue for PD-L1 and PIK3CA mutation testing; if a biopsy is not feasible, archived tumor tissue samples (formalin-fixed, paraffin-embedded (FFPE) blocks or unstained FFPE slides) may be provided for PD-L1 testing. All testing will be performed at a central laboratory. If the provided tumor tissue sample is deemed unsuitable by the central laboratory for evaluating PD-L1 expression and/or PIK3CA mutation status, the subject cannot be enrolled.
- •Must have at least one measurable lesion as per RECIST v1.1 criteria. Previously irradiated lesions with confirmed progression on imaging may be considered as target lesions.
- •ECOG performance status of 0 or
- •Able to swallow tablets normally.
- •Life expectancy of ≥3 months.
Exclusion Criteria
- •Previous treatment with any PI3K, AKT, or mTOR inhibitor, or prior treatment with toripalimab.
- •Patients with type 1 or type 2 diabetes mellitus.
- •History of interstitial lung disease, drug-induced pneumonitis, pulmonary fibrosis, pneumoconiosis, or radiation pneumonitis (patients with only radiographic evidence of radiation pneumonitis and not requiring corticosteroid therapy may be enrolled). Patients with active pneumonia during screening, severely impaired lung function, or other conditions that may interfere with the detection and management of suspected drug-related pulmonary toxicity.
- •Radiographic evidence of tumor invasion into the bladder or rectum, deemed by the investigator to pose a risk of perforation; or a known history of female reproductive tract fistula (e.g., vesicovaginal fistula, urethrovaginal fistula, cervicovesical fistula, etc.). Patients may be enrolled if the perforation or fistula has been treated with diversion surgery, resection, or repair, and the condition is considered resolved or controlled by the investigator.
- •Currently active bleeding, intra-abdominal abscess, or intestinal obstruction requiring clinical intervention.
- •CT/MRI or other imaging shows tumor invasion or encasement of major blood vessels, indicating a high risk of bleeding.
- •Current clinically significant hydronephrosis. Patients may be enrolled if hydronephrosis is relieved by nephrostomy or ureteral stent placement.
- •Patients with refractory nausea and vomiting, dysphagia, gastrointestinal disorders affecting drug absorption (e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome), or other malabsorption conditions.
- •History of severe allergy, hypersensitivity, or other anaphylactic reactions to the investigational product or any of its excipients.
- •Administration of a live vaccine within 4 weeks prior to randomization or planned administration during the study.
Arms & Interventions
WX390 1.1mg + Toripalimab 240mg
Experimental
Participants will receive WX390 continuous oral dosing (1.1 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
Intervention: WX390 1.1mg + Toripalimab 240mg (Drug)
Investigator's Choice of Chemotherapy
Active Comparator
Intervention: Investigator's Choice of Chemotherapy (Drug)
Outcomes
Primary Outcomes
Overall survival in cervical cancer patients who have failed at least one prior line of platinum-based therapy
Time Frame: through study completion, an average of 3 years
Secondary Outcomes
- Efficacy including ORR was assessed by both the investigator and a Blinded Independent Central Review committee according to RECIST v1.1 criteria.(through study completion, an average of 1 year)
- Adverse Events (AEs), including type, incidence, grading (assessed according to the NCI-CTCAE v5.0 criteria), severity, and relationship to the investigational drug, among others.(through study completion, an average of 3 years)
- Efficacy including DCR was assessed by both the investigator and a Blinded Independent Central Review committee according to RECIST v1.1 criteria.(through study completion, an average of 1 year)
- Efficacy including DoR was assessed by both the investigator and a Blinded Independent Central Review committee according to RECIST v1.1 criteria.(through study completion, an average of 1 year)
Investigators
Similar Trials
Recruiting
Phase 3
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07311694Jiangsu HengRui Medicine Co., Ltd.370
Not yet recruiting
Not Applicable
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNCT07309419Shanghai Zhongshan Hospital222
Not yet recruiting
Phase 2
SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaNCT07374549CSPC Megalith Biopharmaceutical Co.,Ltd.100
Not yet recruiting
Not Applicable
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate CancerNCT07268794Fudan University112
Not yet recruiting
Phase 2
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerNCT07348861Zheng Min25